trending Market Intelligence /marketintelligence/en/news-insights/trending/di4pxy6uv-wodk-3tk-7fq2 content esgSubNav
In This List

Regulus Therapeutics director to retire

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


Regulus Therapeutics director to retire

Regulus Therapeutics Inc. said director Mark Foletta will retire from the board upon the expiration of his current term ending at the 2018 annual meeting of stockholders.

The San Diego, Calif.-based company said Foletta's decision was a result of his concurrent service as the executive vice president and CFO for cancer drug developer Tocagen Inc.